Scholarlink

Purpose of Review <p>To summarize advances in transcatheter patent ductus arteriosus (PDA) device closure, with a particular focus on premature infants. This review emphasizes early and late post-procedural outcomes and highlights device innovation as well as the need for further studies evaluating clinical changes following closure.</p> Recent Findings <p>Transcatheter PDA closure has become the standard of care for PDA closure in premature infants given the improved safety profiles and reduced procedural morbidity compared to surgical ligation. FDA approval of the Amplatzer Piccolo Occluder in 2019 for use in extremely low birth weight (ELBW) infants ≥ 700&#xa0;g has allowed for closure in smaller, higher risk patients, enabling further investigation into short-term and long-term outcomes in this population.</p> Summary <p>PDA closure traditionally relied on medical and surgical approaches, with a catheter-based approach now the standard of care. While outcomes in term and older infants are well established, growing clinical experience and the availability of smaller profile devices such as the Piccolo Occluder, have enabled safe and effective closure in this high-risk population. These advances have driven continued interest in evaluating short- and long-term post-procedural outcomes, with a growing interest in understanding the clinical trajectories following closure.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Advances in Patent Ductus Arteriosus Device Closure

  • 期刊论文

  • 发表日期：

    2025年10月30日

查看全文
  • Nicole Parada Parra,
  • Mariel Turner,
  • Oliver M. Barry

摘要

Purpose of Review

To summarize advances in transcatheter patent ductus arteriosus (PDA) device closure, with a particular focus on premature infants. This review emphasizes early and late post-procedural outcomes and highlights device innovation as well as the need for further studies evaluating clinical changes following closure.

Recent Findings

Transcatheter PDA closure has become the standard of care for PDA closure in premature infants given the improved safety profiles and reduced procedural morbidity compared to surgical ligation. FDA approval of the Amplatzer Piccolo Occluder in 2019 for use in extremely low birth weight (ELBW) infants ≥ 700 g has allowed for closure in smaller, higher risk patients, enabling further investigation into short-term and long-term outcomes in this population.

Summary

PDA closure traditionally relied on medical and surgical approaches, with a catheter-based approach now the standard of care. While outcomes in term and older infants are well established, growing clinical experience and the availability of smaller profile devices such as the Piccolo Occluder, have enabled safe and effective closure in this high-risk population. These advances have driven continued interest in evaluating short- and long-term post-procedural outcomes, with a growing interest in understanding the clinical trajectories following closure.